Acute leukaemia during azathioprine therapy

Area of Science:

• Immunosuppressive therapy
• Hematologic malignancies
• Pharmacovigilance

Background:

• Azathioprine is an immunosuppressive drug commonly used in organ transplantation and autoimmune diseases.
• Previous reports have linked azathioprine to various malignancies, particularly lymphomas.
• The association between azathioprine and non-lymphoid cancers, especially in non-transplant patients, is less well-documented.

Observation:

• A case of acute myeloid leukemia (AML) is presented.
• The patient was undergoing azathioprine therapy for rheumatoid arthritis.
• This represents the third reported instance of leukemia developing during azathioprine treatment for a non-malignant condition.

Findings:

• This case adds to the limited evidence suggesting a potential link between azathioprine and the development of acute myeloid leukemia.
• The occurrence of AML in a patient treated for rheumatoid arthritis highlights the need for vigilance regarding azathioprine's oncogenic potential in diverse clinical settings.
• Further research is warranted to elucidate the mechanisms underlying this association.

Implications:

• Clinicians should be aware of the potential risk of hematologic malignancies, including AML, in patients receiving azathioprine therapy, even for non-malignant indications.
• Enhanced monitoring for early signs of leukemia may be considered in patients on long-term azathioprine treatment.
• This case underscores the importance of pharmacovigilance in identifying rare adverse drug reactions and potential drug-induced cancers.